Skip to main content

Table 2 Outcomes of assisted reproduction treatment cycles after pretreatment with either GnRH agonist or Dienogest

From: Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial

Outcome GnRH agonist Dienogest P-value
Total dose of FSH (IU)a 2047 ± 67.7 2180 ± 57.4 0.65
No. of oocytea 11.4 ± 1.2 11.1 ± 1.4 0.78
No. of mature oocytesa 6.6 ± 1.3 6 ± 1.8 0.71
Fertilization rate (%) b 40.3% 47.67% 0.38
No. of transferrable embryosa 4.5 ± 1.8 5.1 ± 2.1 0.63
Transferred embryo b
 Cleavage stage 37 (55.22%) 42 (62.69%) 0.37
 Blastocyst stage 30 (44.78%) 25 (37.31%)
Pregnancy rate (%) b 15/67 (22.39%) 1 7/67 (25.37%) 0.69
Clinical pregnancy rate (%) b 12/67 (17.91%) 17/67 (25.37%) 0.29
Miscarriage rate (%) b 2/15 (13.3%) 0
Cost of pretreatment /ovarian stimulation (EGP)a 3664 ± 45.1 2773 ± 38.1 < 0.001
  1. EGP Egyptian Pounds, GnRHa Gonadotropin-releasing hormone agonist, FSH Follicle-stimulating Hormone
  2. aValues are expressed as means ± standard deviations
  3. bValues expressed as numbers and percentages